Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
311.37
+3.30 (1.07%)
Sep 30, 2025, 3:37 PM EDT - Market open
Cencora Revenue
Cencora had revenue of $80.66B in the quarter ending June 30, 2025, with 8.65% growth. This brings the company's revenue in the last twelve months to $316.65B, up 11.56% year-over-year. In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth.
Revenue (ttm)
$316.65B
Revenue Growth
+11.56%
P/S Ratio
0.19
Revenue / Employee
$6,883,791
Employees
46,000
Market Cap
60.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
COR News
- 20 days ago - Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 20 days ago - Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 25 days ago - Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Cencora Appoints Mark Durcan as Chairman of Its Board of Directors - Business Wire
- 7 weeks ago - Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap - Seeking Alpha
- 7 weeks ago - Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy - Seeking Alpha
- 7 weeks ago - Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Cencora raises annual profit forecast on strong demand for specialty drugs - Reuters